Public health updates

Public health3 days agoCanada

Sandoz Canada reports Erelzi 25 mg supply disruption until February 2027

Sandoz Canada reports its Erelzi (etanercept) 25 mg solution for subcutaneous injection (DIN 02462877) faces an anticipated shortage from Nov 2, 2026 to Feb 12, 2027, after a disruption in manufacturing.

Etanercept is used for arthritis and other autoimmune conditions — patients and prescribers should plan the switch to another product before Nov 2.

Public health3 days agoCanada

Bayer reports supply shortage of 500 mg Cipro oral suspension until March

Bayer reports its Cipro oral suspension (ciprofloxacin) 500 mg (DIN 02237514) is in an actual shortage that began Oct 23, 2026 and is expected to run until Mar 1, 2027, due to supply constraints.

Ciprofloxacin suspension is used for children and patients who cannot swallow tablets — pharmacies should check stock and alternatives while the shortage runs.

Due in 25 daysPublic health3 days agoCanada

Mylan reports 15 mg mirtazapine tablet shortage through November 24

Mylan Pharmaceuticals reports its Mylan-Mirtazapine 15 mg tablet (DIN 02256096) faces an anticipated shortage that began Oct 26, 2026 and is expected to run until Nov 24, 2026, after a disruption in manufacturing.

Mirtazapine is a commonly prescribed antidepressant — prescribers and pharmacies should plan alternatives while the shortage runs.

Due in 2 daysPublic health3 days agoCanada

Sandoz Canada to discontinue 50 mg diclofenac suppositories starting November 2026

Sandoz Canada reports its Sandoz-Diclofenac (diclofenac sodium) 50 mg suppository (DIN 02261928) faces an anticipated shortage from Nov 1, 2026, because the product is to be discontinued. No expected end date is given.

Diclofenac suppositories are used where oral pain relief is not an option — care teams should plan alternatives before the product is discontinued.

Public health3 days agoCanada

Mylan fluconazole 100 mg tablets face supply disruption until April 13

Mylan Pharmaceuticals reports its Mylan-Fluconazole 100 mg tablet (DIN 02245293) is in an actual shortage that began Oct 13, 2026 and is expected to run until Apr 13, 2027, after a disruption in manufacturing.

Fluconazole is a widely used antifungal — pharmacies should check stock and alternatives while the shortage runs.

Public health3 days agoCanada

BGP Pharma reports manufacturing disruption causing 50 mg Viagra shortage in December

BGP Pharma reports its Viagra (sildenafil) 50 mg tablet (DIN 02239767) faces an anticipated shortage from Dec 10 to Dec 29, 2026, after a disruption in manufacturing.

Sildenafil is widely prescribed — pharmacies should plan stock and alternatives ahead of the December gap.

Public health3 days agoCanada

BGP Pharma reports upcoming 300 mg Neurontin capsule supply disruption

BGP Pharma reports its Neurontin (gabapentin) 300 mg capsule (DIN 02084279) faces an anticipated shortage from Dec 15, 2026 to Jan 5, 2027, after a disruption in manufacturing.

Gabapentin is widely used for nerve pain and seizures — prescribers and pharmacies should plan alternatives before the December gap.

Public health3 days agoCanada

BGP Pharma reports Lyrica 150 mg capsule shortage starting December 6

BGP Pharma reports its Lyrica (pregabalin) 150 mg capsule (DIN 02268450) faces an anticipated shortage from Dec 6, 2026 to Jan 26, 2027, after a disruption in manufacturing.

Pregabalin is widely used for nerve pain and seizures — prescribers and pharmacies should plan alternatives before the December gap.

Public health3 days agoCanada

Sandoz discontinues 50 mg diclofenac potassium tablets effective September 8

Sandoz Canada reports its Sandoz Diclofenac Rapide (diclofenac potassium) 50 mg tablet (DIN 02261774) is in an actual shortage that began Sep 8, 2026, because the product is to be discontinued. No expected end date is given.

Diclofenac is a widely used pain and inflammation drug — prescribers and pharmacies should switch patients to another diclofenac product before this one is discontinued.

Public health3 days agoCanada

BGP Pharma reports Caduet 10 mg 10 mg tablet shortage starting December

BGP Pharma reports its Caduet (amlodipine / atorvastatin) 10 mg / 10 mg tablet (DIN 02273284) faces an anticipated shortage from Dec 15, 2026 to Jan 12, 2027, after a disruption in manufacturing.

Caduet combines a blood-pressure drug and a cholesterol drug in one tablet — patients may need the two drugs separately during the gap.

Public health3 days agoCanada

BGP Pharma reports Zoloft 25 mg shortage lasting until January 5

BGP Pharma reports its Zoloft (sertraline) 25 mg capsule (DIN 02132702) is in an actual shortage that began Oct 9, 2026 and is expected to run until Jan 5, 2027, after a disruption in manufacturing.

Sertraline is one of the most commonly prescribed antidepressants — pharmacies should check stock and alternatives while the shortage runs.

Public health3 days agoCanada

BGP Pharma reports manufacturing shortage of 40 mg Zeldox capsules

BGP Pharma reports its Zeldox (ziprasidone) 40 mg capsule (DIN 02298600) is in an actual shortage that began Oct 6, 2026 and is expected to run until Jan 5, 2027, after a disruption in manufacturing.

Ziprasidone is used to treat schizophrenia and bipolar disorder — care teams should confirm supply and alternatives while the shortage runs.

Public health3 days agoCanada

BGP Pharma reports manufacturing disruption causing shortage of 2 mg Mavik capsules

BGP Pharma reports its Mavik (trandolapril) 2 mg capsule (DIN 02231460) is in an actual shortage that began Sep 23, 2026 and is expected to run until Jan 5, 2027, after a disruption in manufacturing.

Trandolapril is a blood-pressure drug — pharmacies should check stock and alternatives while the shortage runs.

Public health3 days agoCanada

BGP Pharma reports Zoloft 50 mg supply shortage from December to January

BGP Pharma reports its Zoloft (sertraline) 50 mg capsule (DIN 01962817) faces an anticipated shortage from Dec 1, 2026 to Jan 5, 2027, after a disruption in manufacturing.

Sertraline is one of the most commonly prescribed antidepressants — prescribers and pharmacies should plan alternatives before the December gap.

Public health3 days agoCanada

BGP Pharma reports Zoloft 100 mg shortage lasting until January 5

BGP Pharma reports its Zoloft (sertraline) 100 mg capsule (DIN 01962779) is in an actual shortage that began Sep 25, 2026 and is expected to run until Jan 5, 2027, after a disruption in manufacturing.

Sertraline is one of the most commonly prescribed antidepressants — pharmacies should check stock and alternatives while the shortage runs.

Due in 4 daysPublic health3 days agoCanada

BGP Pharma reports one-week supply shortage for 100 mcg Synthroid tablets

BGP Pharma reports its Synthroid (levothyroxine sodium) 100 mcg tablet (DIN 02172100) faces an anticipated shortage starting Oct 26, 2026 and expected to end Nov 3, 2026, driven by increased demand.

Levothyroxine is one of the most commonly prescribed drugs in Canada — even a one-week gap matters, so pharmacies should check stock now.

Due in 16 daysPublic health4 days agoCanada

Accel Pharma reports upcoming two-week shortage of ondansetron 8 mg tablets

Accel Pharma reports its ondansetron orally-disintegrating tablet 8 mg (ACCEL-ONDANSETRON ODT, DIN 02535327) faces an anticipated shortage from Nov 1 to Nov 15, 2026, caused by a shortage of an active ingredient.

Ondansetron is a widely used anti-nausea drug — pharmacies should check stock and alternatives before the anticipated shortage starts Nov 1.

Due in 16 daysPublic health4 days agoCanada

Accel Pharma reports upcoming two-week shortage of ondansetron 4 mg tablets

Accel Pharma reports its ondansetron orally-disintegrating tablet 4 mg (ACCEL-ONDANSETRON ODT, DIN 02535319) faces an anticipated shortage from Nov 1 to Nov 15, 2026, caused by a shortage of an active ingredient.

Ondansetron is a widely used anti-nausea drug — pharmacies should check stock and alternatives before the anticipated shortage starts Nov 1.

Due in 35 daysPublic health4 days agoCanada

Sandoz rabeprazole 20 mg supply disruption expected until early December

Sandoz Canada reports its rabeprazole sodium 20 mg enteric-coated tablet (DIN 02314185) faces an anticipated shortage from Oct 26 to Dec 4, 2026, after a disruption in the manufacture of the drug.

Rabeprazole is a commonly prescribed stomach-acid drug — prescribers and pharmacies should plan alternatives while the shortage is expected.

Due in 14 daysPublic health4 days agoCanada

Sandoz dexamethasone injection supply faces temporary shortage through mid-November

Sandoz Canada reports its dexamethasone sodium phosphate injection 10 mg/mL (DIN 00874582), for intravenous, intramuscular or intrasynovial use, faces an anticipated shortage from Oct 26 to Nov 13, 2026, driven by increased demand.

Dexamethasone injection is a staple steroid in hospitals and clinics — care teams should check stock before the anticipated shortage bites.

Due in 7 daysPublic health4 days agoCanada

Sandoz reports supply shortage of sufentanil injection through early November

Sandoz Canada reports its sufentanil citrate injection 50 mcg (DIN 02244147), for epidural or intravenous use, is in an actual shortage that began Oct 13, 2026 and is expected to run until Nov 6, 2026, driven by increased demand.

Sufentanil is used in anaesthesia and pain care — hospitals should confirm supply and alternatives while the shortage runs.

Due todayPublic health4 days agoCanada

Piperacillin-tazobactam injection from Sandoz in short supply until Oct 30 after shipping delay

Sandoz Canada reports its piperacillin and tazobactam powder for injection (DIN 02521539) is in an actual shortage that began Oct 19, 2026 and is expected to run until Oct 30, 2026, caused by a delay in shipping.

Piperacillin-tazobactam is a widely used IV antibiotic — hospitals should check stock and alternatives while the shortage runs.

Public health4 days agoCanada

Baxter to discontinue 200 mg cyclophosphamide intravenous solution by year end 2026

Baxter Corporation reports its Procytox (cyclophosphamide) 200 mg powder for intravenous solution (DIN 02241797) will be discontinued on Dec 31, 2026, for business reasons. The discontinuation decision will not be reversed.

Cyclophosphamide is a standard chemotherapy drug — cancer care teams should plan the switch to another strength or product before Dec 31.

Public health5 days agoCanada

Elective egg freezing cycles see sharp increase among Canadians

Egg-freezing retrievals in Canada rose from 217 cycles in 2013 to 2,663 in 2025, with over 22,000 eggs banked last year, up from 775, per the Canadian Fertility and Andrology Society. Doctors cite high living costs, career ambitions, later parenthood and a lack of a partner. A cycle typically costs $11,000-$16,000 with medication and a year of storage, and public funding does not cover elective freezing. Freezing 20-25 eggs in the early 30s gives about a 75% chance of a baby, but success is never guaranteed - and only about 11% of people who froze eggs have gone back to thaw them.

Elective fertility preservation is surging while staying out of reach for many: a cycle costs $11,000-$16,000 with no public funding. Anyone considering it should know the costs, the odds, and that a fertility-clinic consultation is the recommended first step.

Public health6 days agoCanada

Prince Edward Island launches provincial alcohol strategy to address health care impacts

P.E.I. released a 16-recommendation alcohol strategy after five years of planning, aiming to reduce drinking rather than ban it. Measures include screening for high-risk drinking at medical appointments, youth programs, pricing by alcohol content, and putting 3 per cent of net alcohol profits into community and harm-reduction work. Alcohol causes about 7,000 ER visits and hospitalizations a year on the Island, and impaired driving rates are nearly three times the national average.

The strategy links alcohol policy directly to health care: screening in clinics, and a share of liquor profits funding harm reduction.

Public health6 days agoCanada

Early influenza season hits Canada as vaccination campaigns commence for health workers

Canada’s flu season began seven weeks earlier than usual, with national positivity rates exceeding the five per cent epidemic threshold by mid-October. While H1N1 is the dominant strain, experts note that current vaccines remain effective at reducing the severity of illness and the risk of hospitalization.

You can now offer patients the current flu vaccine, which remains effective against the dominant H1N1 strain.

ResearchTech & trendsOct 23, 2026Canada

Personalized mRNA vaccine reduces melanoma recurrence risk in clinical trial

Moderna and Merck's personalized mRNA vaccine intismeran cut the risk of melanoma returning by 42 per cent two years after surgery, in a study of more than 1,100 people with high-risk melanoma. Two years on, 82 per cent of vaccinated patients were recurrence-free, versus 70 per cent on Keytruda alone. The companies are discussing approval with regulators; full results were due at a European oncology meeting in Madrid.

A personalized mRNA vaccine, matched to each patient's tumour, is moving toward approval after a large trial showed a clear gain in living without recurrence.